Oramed Pharmaceuticals Inc.
ORMPAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Hold | May 17, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jan 17, 2023 |
| Canaccord Genuity | downgrade | Buy →Hold | Jan 12, 2023 |
| Aegis Capital | maintain | Buy | May 16, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Feb 18, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 30, 2021 |
| HC Wainwright & Co. | maintain | Buy | Nov 29, 2021 |
| Aegis Capital | maintain | Buy | Nov 2, 2021 |
| Canaccord Genuity | maintain | Buy | Jul 29, 2021 |
| Aegis Capital | maintain | Buy | Jun 8, 2021 |
| Canaccord Genuity | maintain | Buy | Apr 20, 2021 |
| National Securities Corporation | maintain | Buy | Feb 9, 2021 |
| Aegis Capital | maintain | Buy | Jan 27, 2021 |
| HC Wainwright & Co. | maintain | Buy | Jul 13, 2020 |
| HC Wainwright & Co. | maintain | Buy | Jun 22, 2020 |
| Ladenburg Thalmann | maintain | Buy | Sep 11, 2019 |
| FBR Capital | maintain | Outperform | Nov 19, 2015 |
| H.C. Wainwright | maintain | Buy | Oct 1, 2015 |
| Aegis Capital | maintain | Buy | Dec 4, 2013 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $0.43| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $2.76 | $0.43 | — | — |
| May 19, 2026 | $0.91 | — | — | — |
| Mar 26, 2026 | $-0.06 | $-0.08 | — | $500.0K |
| Nov 13, 2025 | $1.13 | $-0.04 | — | — |
| Aug 14, 2025 | $-0.05 | $-0.04 | — | — |
| May 15, 2025 | $-0.19 | $-0.03 | $2.0M | — |
| Mar 27, 2025 | $0.01 | $-0.03 | — | — |
| Nov 7, 2024 | $-0.48 | $-0.00 | — | — |
News
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 12.7% of Oramed Pharmaceuticals
Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Profitability This table compares Generate Biomedicines and
Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and Scilex have yielded strong returns, including a near tripling of its $38.2M Alpha Tau Medical stake and robust loan recovery from Scilex. Alpha Tau Medical's Alpha DaRT product, with approvals in Japan and Israel and a lucrative U.S. licensing deal, offers substantial upside but…